Feb 7th 2023 - Mar 21st 2023
“Statistically significant improvements in lung fu... See more
there could be a cure/preventative for breast cancer out there
The Motley Fool Stock Advisor has a track record that speaks for itself, with average recommendations that have returned over 542%*. Act now so you can start investing smarter, not harder.
*As of October 2023$79 is an introductory price for new members only. 60% discount based on the current list price of Stock Advisor of $199/year. Membership will renew annually at the then current list price.Feb 8th 2023 - Mar 22nd 2023
$SLRX “These initial data explain why we believ... See more
$SLRX SP-3164 showed significant tumor growth &q... See more
“Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023” Oh, 48 weeks! !
there could be a cure/preventative for breast cancer out there
They have a great product treating cancer with immunotherapy, peer reviewed journal
Alzheimer therapies are on the top of choices.
A drug that actually helps without any major side effects .. and breakthrough therapy. .
Better than chemo.
$AVXL The oral Anavex 2-73 therapy met the primary and secondary endpoints of the trial, with patients receiving the therapy experiencing statistically significant improvement in cognition.
So undervalued cancer bio. 👍
$SLRX “These initial data explain why we believe SP-3164 is so exciting, with the potential to make a positive difference in the treatment of hematologic cancers.
$SLRX SP-3164 showed significant tumor growth "inhibition" in in vivo studies including statistically significant improvement over the approved immunomodulatory drugs lenalidomide (Revlimid®) and pomalidomide (Pomalyst®)
